MacroGenics
As of the edition of 20 October 2026, MacroGenics runs 18 drugs, 2 of them marketed; it is on route A at 3 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 5 |
| Went quiet | 1 |
| Stopped | 10 |
| Total | 18 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Teplizumab | Ends 2034 (computed from the first US licence) | 1 |
| Margetuximab | Ends 2032 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 3 targets, route B at 1 target.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where MacroGenics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 28 trials led
- Skin and connective tissue: 15 trials led
- Digestive system: 12 trials led